Home

Deck

The Cigna Group · CI · NYSE

Cigna is now an Evernorth-led health-services platform: pharmacy benefits and specialty care drive the revenue base, while Cigna Healthcare supplies employer medical, ASO, and international benefits.

$284.04
Price
$74.8B
Market cap
$274.9B
Revenue (FY2025)
188.4M
Customer relationships
Daily price history starts in 1990 at $6.69; it peaked at $366.85 on Sept. 16, 2024, versus the latest staged price of $284.04.
2 · The tension

Cigna kept the PBM volume; now it has to keep the spread.

  • Scale held. Express Scripts processed 2.22B adjusted pharmacy claims in FY2025, and the three largest Evernorth clients are extended through decade-end.
  • Spread cracked. Pharmacy Benefit Services revenue rose 18% in FY2025 while pre-tax income fell 2%; in Q1 FY2026, PBS pre-tax income fell 28% and Evernorth margin dropped to 2.5% from FY2025's 3.1%.
  • Buyers have leverage. One pharmacy-benefit client represented 19% of FY2025 external revenue, and the February 2026 PBM settlement plus federal reforms increase pressure to move rebate and spread economics into explicit-fee negotiations.
The question is not whether Cigna can keep claims. It is whether each retained claim still earns enough profit.
3 · Money picture

The low multiple depends on earnings durability.

$274.9B
FY2025 revenue +11% YoY
3.3%
Operating margin low-spread mix
$7.8B
Free cash flow 1.24x net income
9.4x
FY2026 adjusted P/E $30.35 EPS floor

Revenue growth is not the argument: pharmacy pass-through dollars can rise while profit dollars lag. The long case needs FCF to keep funding buybacks after diluted shares fell 29% from 2019 to 2025, while Evernorth margin proves Q1's 2.5% was not the new run rate.

4 · What changed

Cigna pruned insurance risk and made Evernorth more exposed.

Before: The 2018 Express Scripts deal turned Cigna into a PBM-led health-services platform; FY2019 revenue jumped to $153.6B from $48.7B in FY2018. The pitch worked while cash flowed, but 2024 showed weak spots: adjusted EPS missed the $28.40 guide at $27.33 and VillageMD produced a $2.7B after-tax investment loss.

Pivot: The HCSC sale closed on March 19, 2025 with $4.9B of final cash proceeds, removing owned Medicare Advantage and related risk. On April 30, 2026, management said Cigna will exit ACA individual exchanges after 2026 and review eviCore alternatives.

Today: Q1 FY2026 Cigna Healthcare revenue fell 21% after divestiture, yet pre-tax income rose 18% and MCR improved to 79.8%. That supports the pruning story, but only if full-year MCR stays inside the 83.7% to 84.7% range.

The portfolio got easier to read, not easier to underwrite.
5 · Cash quality

The cash is real; the bridge is not clean.

  • Cash passes the first test. FY2025 operating cash flow was $9.6B against $6.0B of shareholders' net income, and FY2025 FCF was $7.8B.
  • Receivables moved the wrong way. FY2025 receivables rose 18.7% versus 11.2% revenue growth, DSO reached 35.2 days, and manufacturer receivable factoring totaled $4.4B.
  • Adjusted earnings need discipline. FY2025 adjusted income was $8.014B versus $5.957B GAAP net income; FCF after acquisitions fell from $9.033B in FY2023 to $6.093B in FY2025.
This is a multiple haircut, not a thesis breaker: cash funds repurchases, but 2H26 has to prove conversion without working-capital help.
6 · Bull & Bear

Valuation helps; Evernorth has to confirm.

  • For. At $284.04, Cigna trades at 9.4x management's FY2026 adjusted EPS floor of $30.35; 10x and 12x scenarios frame roughly $303 and $364.
  • For. FY2025 FCF was $7.8B, net debt/EBITDA was 2.0x, and diluted shares fell 29% from 2019 to 2025, so buybacks can add value if earnings hold.
  • Against. If Q1's 2.5% Evernorth margin is the new run rate, the low multiple is easier to justify because retained PBM volume is coming with lower profit per claim.
  • Against. The CEO handoff on July 1, 2026 and September Investor Day land during FTC settlement implementation, federal PBM reforms, and the Signature rebate-free model transition.
My view: valuation gets attention, but operating evidence has to earn conviction. A FY2026 Evernorth income guide below $6.9B or margin at or below 2.5% through Q2-Q3 would challenge the lean.

Watchlist to re-rate: Q2 earnings on July 30, 2026: Evernorth margin/PBS income and Healthcare MCR; 2H26 cash-flow bridge: receivables, factoring, and adjusted-to-GAAP gap; price confirmation: close above $295 or below $258.